Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.
Cancellation of kids’ asthma medication continues to cause turmoil for Mass. families
Massachusetts families are still struggling to find alternatives almost a year after GlaxoSmithKline canceled a widely ...
Sell Rating for GlaxoSmithKline Amidst Competitive Pressures from Gilead in HIV Market
Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated ...
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...
pharmaphorum2d
FDA clears GSK's Priorix, first new MMR vaccine in 50 years
With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...
WJET Erie on MSN2mon
Drugmaker to settle nearly 80,000 Zantac lawsuits for up to $2.2 billion
UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
India Infoline5d
Glaxosmithkline Pharmaceuticals Ltd Summary
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is ...